Latest Posts

February 5, 2021 – PathGroup is pleased to announce the availability of a new serologic test for the detection of human antibodies to the SARS-CoV-2 spike protein (S) receptor binding domain (RBD), the viral pathogen associated with SARS-CoV-2 (COVID-19). The Roche Elecsys® Anti-SARS-CoV-2 S antibody test is for the qualitative and semi-quantitative detection of total antibodies (IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection and is intended to aid in identification of patients with an adaptive immune response to SARS-CoV-2 indicating prior infection to the SARS-CoV-2 virus. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for this test.

Click Here to learn more.

The American Medical Association makes updates to the Current Procedural Terminology (CPT) codes each year. Effective January 1, 2021, there will be CPT code changes for laboratory tests and/or components of tests provided by PathGroup.

Click here to learn more.

Effective May 27, 2020, PathGroup is pleased to announce the availability of a new serologic test for human antibodies to SARS-Cov-2, the viral pathogen associated with COVID-19 (PathGroup Test Code: COVIDAB). On May 3, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Roche Elecsys® SARS-CoV-2 antibody test. The test is for the qualitative detection of total antibodies (including IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection. This test may aid in identification of patients with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection to the SARS-CoV-2 virus.

Click Here to for more information.